Literature DB >> 7094203

Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.

S J Appelbaum, M Mayersohn, R T Dorr, D Perrier.   

Abstract

Six normal, healthy adult males received a single dose of allopurinol intravenously, orally in the form of a commercial tablet, and rectally in the form of an extemperaneously prepared suppository (either in a cocoa butter or in polyethylene glycol base). Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean (+/- SD) values were obtained from the intravenous allopurinol experiment: clearance, 9.62 +/- 3.49 ml . kg-1 . min-1; Vd, 1.61 +/- 0.74 l/kg; t1/2, 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67% +/- 23%, while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects. Current use of rectal dosage forms as an adjunct in cancer chemotherapy should therefore be re-examined.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094203     DOI: 10.1007/BF00292878

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT.

Authors:  J R KLINENBERG; S E GOLDFINGER; J E SEEGMILLER
Journal:  Ann Intern Med       Date:  1965-04       Impact factor: 25.391

2.  PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.

Authors:  I H KRAKOFF; R L MEYER
Journal:  JAMA       Date:  1965-07-05       Impact factor: 56.272

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  Hyperuricemic acute renal failure.

Authors:  C M Kjellstrand; D C Cambell; B von Hartitzsch; T J Buselmeier
Journal:  Arch Intern Med       Date:  1974-03

5.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

6.  Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease.

Authors:  R C DeConti; P Calabresi
Journal:  N Engl J Med       Date:  1966-03-03       Impact factor: 91.245

7.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

8.  EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT.

Authors:  T F YUE; A B GUTMAN
Journal:  Am J Med       Date:  1964-12       Impact factor: 4.965

9.  Bioavailability of allopurinol oral and rectal dosage forms.

Authors:  S L Chang; W G Kramer; S Feldman; R Ballentine; L S Frankel
Journal:  Am J Hosp Pharm       Date:  1981-03

10.  Allopurinol kinetics.

Authors:  K Hande; E Reed; B Chabner
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

  10 in total
  8 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

2.  Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

Authors:  K Turnheim; P Krivanek; R Oberbauer
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

4.  Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; M Suda; K Higashino
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

5.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Authors:  Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2013-03-10       Impact factor: 2.953

6.  Allopurinol and oxypurinol in human breast milk.

Authors:  I Kamilli; U Gresser
Journal:  Clin Investig       Date:  1993-02

Review 7.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.

Authors:  Lisa Cammalleri; Mariano Malaguarnera
Journal:  Int J Med Sci       Date:  2007-03-02       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.